82 Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): Interim results of a randomised controlled trial

Abstract
No abstract available

This publication has 0 references indexed in Scilit: